Leerink Partners Initiates Coverage on Akebia Therapeutics (NASDAQ:AKBA)
Equities researchers at Leerink Partners started coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $7.00 price target on the biopharmaceutical company’s stock. Leerink Partners’ price target suggests a potential upside of 188.07% […]
Equities researchers at Leerink Partners started coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $7.00 price target on the biopharmaceutical company’s stock. Leerink Partners’ price target suggests a potential upside of 188.07% […]
